3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, bromide (1:1), (1a,2b,4b,5a,7b)- cas no:155-41-9

Synonyms: 1aH,5aH-Tropanium, 6b,7b-epoxy-3a-hydroxy-8-methyl-,bromide, (-)-tropate (8CI); 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, bromide, [7(S)-(1a,2b,4b,5a,7b)]-; 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, bromide, (1a,2b,4b,5a,7b)- (9CI); N-Methylscopolammonium bromide (6CI,7CI);3-Oxa-9-azatricyclo[3.3.1.02,4]nonane, 3-oxa-9-azoniatricyclo[3.3.1.02,4]nonanederiv.; Tropic acid, (-), ester with 6b,7b-epoxy-3a-hydroxy-8-methyl-1aH,5aH-tropanium bromide (8CI); (-)-Scopolaminemethobromide; (-)-Scopolamine methyl bromide; Ampyrox; Blocan; Diopal;Epoxymethamine bromide; Epoxytropine tropate methylbromide; Holopon; Hyoscinemethobromide; Hyoscine methyl bromide; Lescopine bromide; Mescopil;Methscopolamin bromide; Methscopolamine bromide; Methylscopolamine bromide;N-Methylscopolamine bromide; N-Methylscopolaminium bromide; NSC 120606; NSC61809; Neo-Avagal; Nutrop; Pamine; Pamine bromide; Paraspan; Proscomide;Restropin; Scopolamine methobromide; Scopolamine methyl bromide; U 5036
Name3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, bromide (1:1), (1a,2b,4b,5a,7b)-
CAS155-41-9
Synonyms1aH,5aH-Tropanium, 6b,7b-epoxy-3a-hydroxy-8-methyl-,bromide, (-)-tropate (8CI); 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, bromide, [7(S)-(1a,2b,4b,5a,7b)]-; 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, bromide, (1a,2b,4b,5a,7b)- (9CI); N-Methylscopolammonium bromide (6CI,7CI);3-Oxa-9-azatricyclo[3.3.1.02,4]nonane, 3-oxa-9-azoniatricyclo[3.3.1.02,4]nonanederiv.; Tropic acid, (-), ester with 6b,7b-epoxy-3a-hydroxy-8-methyl-1aH,5aH-tropanium bromide (8CI); (-)-Scopolaminemethobromide; (-)-Scopolamine methyl bromide; Ampyrox; Blocan; Diopal;Epoxymethamine bromide; Epoxytropine tropate methylbromide; Holopon; Hyoscinemethobromide; Hyoscine methyl bromide; Lescopine bromide; Mescopil;Methscopolamin bromide; Methscopolamine bromide; Methylscopolamine bromide;N-Methylscopolamine bromide; N-Methylscopolaminium bromide; NSC 120606; NSC61809; Neo-Avagal; Nutrop; Pamine; Pamine bromide; Paraspan; Proscomide;Restropin; Scopolamine methobromide; Scopolamine methyl bromide; U 5036
EINECS(EC#)205-844-5
Molecular FormulaC18H24 N O4 . Br
Molecular Weight398.34
Appearancewhite powder
refractive index-24 ° (C=1, H2O)
Hazard T,N
Risk 23/24/25-50/53-20/21/22
Safety
Poison by intravenous route. Moderately toxic by ingestion, subcutaneous, and intraduodenal routes. When heated to decomposition it emits very toxic fumes of NOx, NH3, and Br−. See also BROMIDES and SCOPOLAMINE.
Hazard Codes: T
,N.gif)
Risk Statements:
23: Toxic by inhalation
24: Toxic in contact with skin
25: Toxic if swallowed
50: Very Toxic to aquatic organisms
53: May cause long-term adverse effects in the aquatic environment
Safety Statements:
36: Wear suitable protective clothing
37: Wear suitable gloves
39: Wear eye/face protection
45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
60: This material and/or its container must be disposed of as hazardous waste
61: Avoid release to the environment. Refer to special instructions safety data sheet
1. |
|
orl-rat LD50:3400 mg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 180 (1969),155. |
2. |
|
scu-rat LD50:2060 mg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 180 (1969),155. |
3. |
|
idu-rat LD50:870 mg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 180 (1969),155. |
4. |
|
orl-mus LD50:1214 mg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 156 (1965),467. |
5. |
|
scu-mus LD50:880 mg/kg
|
|
ARZNAD Arzneimittel-Forschung. Drug Research. 18 (1968),1132. |
6. |
|
ivn-mus LD50:26,806 µg/kg
|
|
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 103 (1955),100. |